Comments
Drug firm Divis Laboratories’ facility near Visakhapatnam has been inspected by the US drug regulator early this month for its “custom manufactured product”.
The Unit II at village Chippada near Visakhapatnam has had an inspection by the United States Food and Drug Administration (USFDA) with no major observations, Divis Laboratories said in a filing to BSE.
“The audit concluded with one observation primarily about further improvement of existing procedure. The purpose of this inspection was for custom manufactured product,” it added.
Divis undertakes custom manufacture of active pharmaceutical ingredients (APIs) and advanced intermediates.
Shares of Divis Laboratories on Friday closed up by 3 per cent at Rs 1,270.40 on BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.